Search

Author/Creator Lam, Anna P

1. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Issue 3 (March 2022)

Authors:
Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jas...
Journal:
Lancet
Issue:
Volume 10:Issue 3(2022)
Page Start:
267
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1 signalling. Issue 2 (15th September 2011)

Authors:
Mutlu, Gökhan M; Budinger, G R Scott; Wu, Minghua; Lam, Anna P; Zirk, Aaron; Rivera, Stephanie; Urich, Daniela; Chiarella, Sergio E; Go, Leonard H T; Ghosh, Asish K; Selman, Moises; Pardo, Annie; Varga, John; Kamp, David W; Chandel, Navdeep S; Sznajder, Jacob Iasha; Jain, Manu
Journal:
Thorax
Issue:
Volume 67:Issue 2(2012)
Page Start:
139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search